Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.

Szczegóły
Abstrakt

Tytuł:: Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine.
Autorzy:: Kikuchi T; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan. taku_k_.
Mori T; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Ohwada C; Department of Hematology, Chiba University Hospital, Chiba, Japan.; Department of Hematology, International University of Health and Welfare School of Medicine, Chiba, Japan.
Onoda M; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Shimizu H; Department of Hematology, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan.
Yokoyama H; Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Onizuka M; Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
Koda Y; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Kato J; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Takeda Y; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Hino Y; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Mishina T; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Sakaida E; Department of Hematology, Chiba University Hospital, Chiba, Japan.
Shono K; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Nagao Y; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Yokota A; Department of Internal Medicine, Chiba Aoba Municipal Hospital, Chiba, Japan.
Matsumoto K; Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Morita K; Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Doshisha Women's College of Liberal Arts, Kyoto, Japan.
Okamoto S; Division of Hematology, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan.
Corporate Authors:: Kanto Study Group for Cell Therapy (KSGCT)
Źródło:: International journal of hematology [Int J Hematol] 2021 Jan; Vol. 113 (1), pp. 128-133. Date of Electronic Publication: 2020 Sep 04.
Typ publikacji:: Comparative Study; Journal Article; Multicenter Study
Język:: English
Imprint Name(s):: Publication: 2008- : Tokyo : Springer Japan
Original Publication: Amsterdam : Elsevier Science Publishers, c1991-
MeSH Terms:: Busulfan/*administration & dosage
Busulfan/*pharmacokinetics
Cyclophosphamide/*administration & dosage
Hematopoietic Stem Cell Transplantation/*methods
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Adult ; Age Factors ; Aged ; Cyclophosphamide/pharmacokinetics ; Drug Therapy, Combination ; Female ; Humans ; Male ; Middle Aged ; Prospective Studies ; Transplantation, Homologous ; Treatment Outcome ; Vidarabine/administration & dosage ; Vidarabine/pharmacokinetics ; Young Adult
References:: Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347–53. (PMID: 10.1056/NEJM198312013092202)
Tutschka PJ, Copelan EA, Klein JP. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood. 1987;70:1382–8. (PMID: 10.1182/blood.V70.5.1382.1382)
Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et al. Busulfan bioavailability. Blood. 1994;84:2144–50. (PMID: 10.1182/blood.V84.7.2144.2144)
Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–60. (PMID: 10.1182/blood.V89.8.3055)
Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31–42. (PMID: 7581127)
Kim SE, Lee JH, Choi SJ, Lee JH, Ryu SG, Lee KH. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan. Haematologica. 2005;90:285–6. (PMID: 15710597)
Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant. 2002;8:493–500. (PMID: 10.1053/bbmt.2002.v8.pm12374454)
Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood. 2003;102:820–6. (PMID: 10.1182/blood-2002-11-3567)
de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857–64. (PMID: 10.1182/blood-2004-02-0414)
Kanakry CG, O’Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, et al. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014;32:3497–505. (PMID: 10.1200/JCO.2013.54.0625)
Yeh RF, Pawlikowski MA, Blough DK, McDonald GB, O’Donnell PV, Rezvani A, et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2012;18:265–72. (PMID: 10.1016/j.bbmt.2011.06.013)
de Castro FA, Lanchote VL, Voltarelli JC, Colturato VA, Simoes BP. Influence of fludarabine on the pharmacokinetics of oral busulfan during pretransplant conditioning for hematopoietic stem cell transplantation. J Clin Pharmacol. 2013;53:1205–11. (PMID: 23955479)
Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:1099–107. (PMID: 10.1016/j.bbmt.2011.12.584)
Rezvani AR, McCune JS, Storer BE, Batchelder A, Kida A, Deeg HJ, et al. Cyclophosphamide followed by intravenous targeted busulfan for allogeneic hematopoietic cell transplantation: pharmacokinetics and clinical outcomes. Biol Blood Marrow Transplant. 2013;19:1033–9. (PMID: 10.1016/j.bbmt.2013.04.005)
Bonin M, Pursche S, Bergeman T, Leopold T, Illmer T, Ehninger G, et al. F-ara-A pharmacokinetics during reduced-intensity conditioning therapy with fludarabine and busulfan. Bone Marrow Transplant. 2007;39:201–6. (PMID: 10.1038/sj.bmt.1705565)
Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2002;8:477–85. (PMID: 10.1053/bbmt.2002.v8.pm12374452)
Ryu SG, Lee JH, Choi SJ, Lee JH, Lee YS, Seol M, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:1095–105. (PMID: 10.1016/j.bbmt.2007.06.005)
Chow DS, Bhagwatwar HP, Phadungpojna S, Andersson BS. Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples. J Chromatogr B Biomed Sci Appl. 1997;704:277–88. (PMID: 10.1016/S0378-4347(97)00419-2)
Matsumoto K, Uchida N, Sakurai A, Taniguchi S, Morita K. Clinical application of the dried blood spot method in the measurement of blood busulfan concentration. Biol Blood Marrow Transplant. 2016;22:1968–73. (PMID: 10.1016/j.bbmt.2016.07.008)
Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8. (PMID: 10.1038/bmt.2012.244)
Almog S, Kurnik D, Shimoni A, Loebstein R, Hassoun E, Gopher A, et al. Linearity and stability of intravenous busulfan pharmacokinetics and the role of glutathione in busulfan elimination. Biol Blood Marrow Transplant. 2011;17:117–23. (PMID: 10.1016/j.bbmt.2010.06.017)
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002;41:93–103. (PMID: 10.2165/00003088-200241020-00002)
Kusama M, Kubota T, Matsukura Y, Matsuno K, Ogawa S, Kanda Y, et al. Influence of glutathione S-transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chim Acta. 2006;368:93–8. (PMID: 10.1016/j.cca.2005.12.011)
Kim SD, Lee JH, Hur EH, Lee JH, Kim DY, Lim SN, et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1222–30. (PMID: 10.1016/j.bbmt.2010.12.708)
Terakura S, Onizuka M, Fukumoto M, Kuwatsuka Y, Kohno A, Ozawa Y, et al. Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning. Int J Hematol. 2020;111:84–92. (PMID: 10.1007/s12185-019-02741-8)
Egorin MJ. Cancer pharmacology in the elderly. Semin Oncol. 1993;20:43–9. (PMID: 8475409)
Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol. 1992;32:271–302. (PMID: 10.1146/annurev.pa.32.040192.001415)
Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood. 1990;75:1723–7. (PMID: 10.1182/blood.V75.8.1723.1723)
Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, et al. Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). Cancer Chemother Pharmacol. 2014;74:927–38. (PMID: 10.1007/s00280-014-2571-0)
Contributed Indexing:: Keywords: Allogeneic stem cell transplantation; Busulfan; Pharmacokinetics
Substance Nomenclature:: 8N3DW7272P (Cyclophosphamide)
FA2DM6879K (Vidarabine)
G1LN9045DK (Busulfan)
P2K93U8740 (fludarabine)
Entry Date(s):: Date Created: 20200905 Date Completed: 20210211 Latest Revision: 20210211
Update Code:: 20240104
DOI:: 10.1007/s12185-020-02990-y
PMID:: 32886279
: Czasopismo naukowe

Full Text Finder

Busulfan (Bu) has been used in combination with fludarabine (Flu; BuFlu) or cyclophosphamide (Cy; BuCy) as conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). This multi-institutional prospective study compared pharmacokinetic (PK) parameters of Bu between BuFlu and BuCy. Plasma Bu concentrations were measured by high-performance liquid chromatography at the first dose of the first and fourth days of intravenous Bu administrations (total of 16 doses of 0.8 mg/kg). Thirty-seven patients were evaluable (BuFlu, N = 18; BuCy, N = 19). The median age was significantly higher in BuFlu. In BuFlu, the median area under the blood concentration-time curve of Bu on the fourth day was 1183 μmol min/L (range 808-1509), which was significantly higher than that on the first day [1095 μmol min/L (range 822-1453), P < 0.01]. In contrast, such differences were not observed in BuCy. Consistently, there was a significant decrease in the clearance of Bu on the fourth day as compared with the first day in BuFlu. These results suggest that the PK of Bu was altered during the co-administration of Flu, which was not the case with Cy. A large-scale study is required to evaluate the significance of the differences in the PK of Bu between the conditionings on HSCT outcomes.

Informacja